Qiagen and Eppendorf form alliance
Qiagen and Eppendorf have announced that they have formed a strategic alliance that includes co-development and co-marketing of complementary and optimised products. The alliance is intended to link the brands and product lines and to ensure the highest compatibility of their products targeting the research, applied testing and molecular diagnostics.
In addition, Qiagen has acquired Eppendorf's reagent business which includes the Eppendorf's Prime nucleic acid sample preparation and PCR reagent product lines and related intellectual property. The acquired assets represent an attractive portfolio of preanalytical and nucleic acid amplification consumables as well as a very promising pipeline of proprietary technologies for nucleic acid handling, separation, purification and amplification.
Through the alliance, Qiagen and Eppendorf intend to focus on improving biological sample management and analysis. The availability of combined and optimised products should create significant benefits for customers in research, applied testing and molecular diagnostics.
Immunologist wins GSK Award for respiratory virus research
Award winner Professor Katherine Kedzierska seeks to answer an important question: why do some...
ATSE names Jane O'Dwyer as its new CEO
O'Dwyer is an executive leader with more than 30 years' experience across higher...
Director of scientific R&D firm fined $195K+ over biogas experiments
The fine follows a 2022 incident in which a doctor sustained serious injuries after exposure to...
